• Breaking News

    Friday, April 30, 2021

    Home Unlabelled Stock Market - S&P 500 visual summary: April 30

    Stock Market - S&P 500 visual summary: April 30

    April 30, 2021

    Stock Market - S&P 500 visual summary: April 30

    S&P 500 visual summary: April 30

    Posted: 30 Apr 2021 01:18 PM PDT

    I analyzed all the Motley Fool Premium recommendations since 2013 and benchmarked them against S&P500 returns. Here are the results!

    Posted: 30 Apr 2021 06:26 AM PDT

    I analyzed all the Motley Fool Premium recommendations since 2013 and benchmarked them against S&P500 returns. Here are the results!

    Preamble: There is no way around it. A vast majority of us Redditors absolutely hate The Motley Fool. I feel that it's justified, given their clickbait titles or "5 can't miss stocks of the century" or turning 1,000 into 100,000 posts designed just to drive traffic to their website. Another Redditor summed it up perfectly with this,

    If r/wallstreetbets and r/stocks can agree on one thing, it's that Motley Fool is utter trash

    Now that that's out of the way, let's come to my hypothesis. There are more than 1 million paying subscribers for Motley Fool's premium subscription. This implies that they are providing some sort of value that encouraged more than 1MM customers to pay up. They have claimed on their website that they have 4X'ed the S&P500 returns over the last 19 years. I wanted to check if this claim is due to some statistical trickery or some outlier stocks which they lucked out on or was it just plain good recommendations that beat the market.

    Basically, What I wanted to know was this - Would you have been able to beat the market if you had followed their recommendations?

    Where is the data from: The data is from Motley Fool Premium subscription (Stock Advisor) in Canada. Due to this, the data is limited from 2013 and they have made a total of 91 recommendations for US-listed stocks. (They make one buy recommendation every 4th Wednesday of the month). I feel that 8 years is a long enough time frame to benchmark their performance. If you have seen my previous posts, I always share the data used in the analysis. But in this case, I will not be able to share the data as per the terms and conditions of their subscription.

    Analysis: As per Motley Fool, their stock picks are long-term plays (at least 5 years). Hence for all their recommendations I calculated the stock price change across 4 periods and benchmarked it against S&P500 returns during the same period.

    a. One-Quarter

    b. One Year

    c. Two Year

    d. Till Date (From the day of recommendation to Today)

    Another feedback that I received for my previous analysis was starting price point for analysis. In this case, Motley Fool recommends their stock picks on Wed market close, I am considering the starting point of my analysis on Thursday's market close price (i.e, you could have bought the share anytime during the next day).

    Results:

    https://preview.redd.it/qg04a2wabbw61.png?width=623&format=png&auto=webp&s=0486800be95f3c49097df601935236a2bc500b11

    As we can see from the above chart, Motley Fool's recommendations did beat the market over the long term across the different time periods. Their one-year returns were ~2X and two-year returns were ~3X the SPY returns. Even capping for outliers (stocks that gained more than 100%), their returns were better than the S&P benchmark.

    https://preview.redd.it/xq68n5kbbbw61.png?width=623&format=png&auto=webp&s=327a831304a22ffb7588037b74da15e2de559e9b

    But it's not like all their strategies were good. As we can see from the above chart, their sell recommendations were not exactly ideal and you would have gained more if you just stayed put on your portfolio and did not sell when they recommended you to sell. One of the major contributors to this difference was that they issued a sell recommendation for Tesla in 2019 for a good profit but missed out on Tesla's 2020 rally.

    How much money should you be managing to profitably use Motley Fool recommendations?

    The stock advisor subscription costs $100 per year. Considering their yearly returns beat the benchmark by 13%, to break even, you only need to invest $770 per year. Considering a 5x factor of safety as historical performance cannot be expected to be repeated and to factor in all the extra trading fees, one has to invest around $4k every year. You also have to factor in the mental stress that you will have to put up with all their upselling tactics and clickbait e-mails that they send.

    Limitations of analysis: Since I am using the Canadian version of Motley Fool's premium subscription, I have only access to the US recommendations made from 2013. But, 8 years is a considerably long time to benchmark returns for the service. Also, I am unable to share the data I used in the analysis for cross-verification by other people.

    But I am definitely not the first person to independently analyze their recommendations. This peer-reviewed research publication in 2017 came to the same conclusion for the time period that was before my analysis.

    We find that the Stock Advisor recommendations do statistically outperform the matched samples and S&P 500 index, since the creation of Stock Advisor in 2002 regarding both short-term and long-term holding periods. Over a longer holding period, the Stock Advisor portfolio repeatedly outperforms the S&P 500 index and matched samples in terms of monthly raw returns and risk-adjusted measures. Although the overall performance of the Stock Advisor portfolio benefits from remarkable recommendation performances between 2002 and 2006, the portfolio still exceeds the benchmarks regarding risk-adjusted measures during the subsequent period between 2007 and 2011

    Conclusion:

    I have some theories on why Motley Fool produces content the way they do. The free articles of the company are just created to drive the maximum amount of traffic to their website. If we have learned anything from the changes in blog headlines and YouTube thumbnails, it's that clickbait works. I guess they must have decided that the traffic they generate from the headlines and articles far outweigh the negative PR they get due to the same articles.

    Whatever the case may be, rather than hating on something regardless of the results, we could give credit where credit is due! I started the research being extremely skeptical, but my analysis, as well as peer-reviewed papers, shows that their Stock Advisor picks beat the market over the long run.

    Disclaimer: I am not a financial advisor and in no way related to Motley Fools.

    submitted by /u/nobjos
    [link] [comments]

    BUFFETT SPEAKS: This Saturday is the Berkshire Annual Meeting and Q1 2021 Earnings. Watch and discuss the event with us at r/brkb

    Posted: 30 Apr 2021 12:33 PM PDT

    BTX up over 100% today. Still going up AH. Opened @ 30.82.

    Posted: 30 Apr 2021 02:21 PM PDT

    Coinbase now allows US users to use PayPal to purchase cryptocurrencies

    Posted: 30 Apr 2021 02:28 PM PDT

    Earnings, spending packages, and more. Here is this weeks recap

    Posted: 30 Apr 2021 04:26 PM PDT

    GEO Group will come in stronger than expected

    Posted: 30 Apr 2021 06:43 AM PDT

    he market is sometimes quick to think in absolutes and the real world is anything but absolute. There are numerous variables that are impacting a business at any given moment in time.
    For GEO, the largest impact of COVID has been the decline in border crossings. With fewer immigrants allowed into the country, they have seen their occupancy decline at their ICE facilities, even as they remained more stable in their other facilities. This was on top of the declines the US had already seen in recent years. Since Trump was elected, 2017 and 2020 were the two lowest years for immigration on record.
    It is hardly a leap to believe that a Biden administration is going to be more immigration friendly. Additionally, the economy is a huge contributor towards the motivation for crossing the border. As the economy recovers from COVID, an improving job environment will encourage more immigrants. The end result is that GEO's occupancy is already at rock bottom. The only place for it to go is up.
    The market is assuming that the blue wave is a negative for GEO. In reality, it is a huge positive for their occupancy levels and as GEO's results improve, their share price will as well.
    Today, you can get an incredible 11% yield that is well covered by cash flows during the COVID impact. GEO's price could easily go back to being in excess of $20, for 230% potential upside.

    submitted by /u/CarlyBriant
    [link] [comments]

    Report: Bitcoin's Moment To Shine Is Very Near

    Posted: 30 Apr 2021 08:17 PM PDT

    $FAMI . Heavily Shorted Stock. 133% Short borrow fee. Recenlty had a share offering which made it reach a 52wk low. Insane volume Pumping to the stock last two days. Keep this one on your radar folks .Charts indicating A bullish Reversal . PT $1+

    Posted: 30 Apr 2021 04:23 PM PDT

    As a Newbie who began his journey this past November with a LT desired hold on all my investments, what now that 70% of them are now worth less than 50% of my initial entered price. P.S. no more $ or desire to average down....

    Posted: 30 Apr 2021 05:37 PM PDT

    This past November I entered the stock market gambling world. Yes, that's how I feel now with all the illegalities I've learned are in play vs normal retailers. I Did do DD but definitely became a victim by choice of the YOUTUBERS Pumps. How very TIMELY during a pandemic. i.e. NIO, GEVO, BNGO, NNDM, HMBL, SNDL, ABML, CHPT, QS, SOS, ZOM to name a few.

    By all DD info and appearances, most NOT bad companies all with unique potentials in their sectors. Lessons learned. HELL, until last week, I was negative on APPL. WTF?

    Now that my cost basis is below 30%, is this normal and as I will not sell for significant losses, will their/do their S/P recover soon or am I looking to be a LT bag holder sucker? Breaking even right now for me would be a win.

    Some will say do you still have conviction in them? My answer is I SADLY DON'T HAVE CONVICTION IN ANYTHING STOCK RELATED ANYMORE. Crooked banks, shorters, greedy HFs and God knows what else is really driving this investing. 😳

    AGAIN, is this normal? Has it happened to you? Will my stocks ever eventually return green again sooner than later as 50% is a lot?

    Just looking for advice and maybe positivity.

    submitted by /u/Humble-Assistant-10
    [link] [comments]

    $MDLZ - A Sweet Buy for the Long Run

    Posted: 30 Apr 2021 10:38 AM PDT

    Company Overview

    Mondelez International Inc. is a consumer business that manufactures and sells snacks and beverages worldwide. It is known as the market leader in biscuits, chocolates, and gums and candies, and owns multiple million-dollar brands such as Cadbury and Milka chocolates, Belvita, Oreo, Trident, Toblerone, and Halls. It sells its products through supermarkets, wholesalers, convenience stores, and other distributors. Mondeleze operates in 80 countries and sells its products in over 150 countries. With a market cap of 84.34 B, they have consistently demonstrated strong financial performance, with revenue and net income of $26.6B and $3.6B USD in 2020.

    Industry Overview

    Mondelez operates in the snack foods industry, which is projected to grow at a CAGR of 4.7% to $688.6 B by 2027. This is driven by a rise in disposable incomes, improving consumer lifestyle, and growing urbanization that increase demand for convenience foods. Key trends include an increased demand for salty and health-conscious snacks, which positions Mondelez well as it generates 43% of revenue from biscuits and has acquired multiple health brands. The largest segment is Europe, while the fastest growing market is China, which provides an advantage for Mondelez, which generates 40% of revenue from Europe and 20% from the Asia Pacific region.

    The mature snack industry is highly fragmented and is dominated by large corporations as well as small local brands. Pepsico is the industry leader, holding 7.1% of market share, while Mondelez (6.9%), Nestle (3.6%), and Kellogg (1.8%) follow. Barriers to entry are low, with many private labels entering with innovative products that could pose a threat to Mondelez' market share. Customers care deeply about flavours and branding, as 68% of customers rely on existing brands rather than new ones, giving Mondelez a competitive advantage.

    Investment Thesis

    Thesis 1: Powerful and Innovative Brands Driving Revenue Growth. Mondelez has a strong economic moat through its brand power, as it owns over 9 brands over $1 billion and numerous "local jewels" that drive organic revenue growth. Its biscuit brands Oreo and Belvita are ranked as the #1 biscuit globally, and their chocolate brands of Cadbury, Milka, and Toblerone are ranked #1 in Europe and AMEA countries. Meanwhile, they hold numerous local jewels such as Lacta, Alpen Gold, and Marabou which rank as the #1 brands in Brazil, Russia, and Sweden respectively. These brands, which make up 75% of its revenue, garner significant brand loyalty, generating operating margins that are ~2% higher than competitors and 2.6% organic revenue growth in 2020.

    Moreover, Mondelez frequently engages in brand innovation, adapting brands to local trends and creating healthy alternatives to adapt to changing consumer preferences through its innovation hub, SnackFutures. Examples include launching Oreo Forbidden City in China in 2018 and amplifying Cadbury Bournvita nutrition credentials in India in 2020, leading to double-digit sales growth in both areas. Mondolez intends to continue its marketing and innovation spend from 2020-2025, positioning it well for the future.

    Thesis 2: Aggressive Acquisition Strategy Creating Strong Runway for Growth. Mondelez's aggressive acquisition strategy of brands in developed and emerging markets creates a strong runway for growth. This strategy is effective for two reasons: it allows them to bolster their product portfolio in high-potential segments and expand geographically, which will drive future revenue. From 2018 to 2020, they have acquired over 6 brands across a variety of food segments with a focus on premium and health foods. Most recently, they acquired Give and Go, a leader in bakery goods, and capitalized on the consumer trend of healthy eating through buying Hu Snack Foods, a leading health food company. These stakes are expected to generate an additional $550M in revenue. Moreover, this acquisition strategy allows them to expand their geographical footprint across nations, with its stake in JDE Peet, the world's largest tea group, increasing their European and global revenues.

    Thesis 3: Strong Management Team with History of Shareholder Value Generation. Mondelez has a strong management team who place emphasis on generating shareholder value. Their compensation system links pay to long-term profitability and incorporates executive stock ownership, incentivizing management to focus on creating shareholder value. Over the past 3 years, their cumulative Total Shareholder Return has been 45.9%, compared to a peer median group's of 18.7%. ROIC and ROE have increased 3% and 6% respectively since 2017, and they have had dividend payouts increasing by 24% per year from $0.82 in 2018 to $1.20 in 2020. They have also consistently generated strong cash flow of ~$2700 since 2017. Management has reaffirmed its 2021 goals to generate organic revenue of +3%, Free Cash Flow of +3B, and to have dividend growth outpace EPS growth, meaning that investors can expect to see significant upside in the future.

    Catalysts & Risks

    (C1) Acquisitions in Health Companies: Mondelez's recent acquisition of Grenade, a Britain protein bar company, will drive European revenue and allow it to capitalize on demand for healthy snacking options.

    (C2) Focus on Sustainability: Mondelez's sustainability initiatives, such as its recent announcement to launch Sustainable Futures, an impact investing platform to support sustainable ventures, will boost brand sentiment.

    (C3) Potential to Surpass First Quarter Earnings: Mondelez has performed strongly in Q1 2021 due to strong demand from their international markets. With the recovery of the global economy driving consumer spending, there is a high chance of beating earnings expectations in Q2, which will drive up stock price.

    (R1) Foreign Exchange: As 75% of Mondelez's revenues come from outside the US, fluctuations in foreign exchange rates will negatively impact earnings. In 2020, FX lowered revenue by 3%.

    (R2) Regulatory Risks: Being a global company, Mondelez is subject to regulatory risks such as the imposition of new tariffs, sanctions, trade barriers, or restrictions on key commodities such as cocoa.

    (R3) Impact of COVID-19 on Emerging Markets: The COVID-19 outbreak could result in lower profits in emerging markets due to disruption of manufacturing and retail operations if social distancing rules are enacted.

    Valuation

    Through conducting a discounted cash flow analysis, I recommend longing MDLZ. At its current share price (April 29, closing) of $60.91, I believe it is undervalued by 12.5% compared to its fair value of $68.50.

    Credit to CynthiaJ32 - original post can be found here

    submitted by /u/cfcm5
    [link] [comments]

    Daily Market Analysis

    Posted: 30 Apr 2021 02:20 PM PDT

    Daily Market Analysis

    For now, it looks like the stock market is in an uptrend. From my experience trading stocks over the years, I have learned that when my stop-loss orders start getting triggered left to right, the market is getting ready to change phases. Multiple stop-losses activated today, telling me that we are perhaps moving from a "stage two" uptrend into a "stage three" sideways trend( weekly timeframe)?

    ​

    As you can see in the picture below, both the $SPY and $QQQ are moving in "stage three" sideways motion (Daily timeframe). I wouldn't be surprised if this soon turns into a "stage four" downward trend (Daily timeframe) from the market's activity.

    ​

    As usual, we cannot predict the market, but we can analyze it and prepare for what may come. Bringing my stop-loss orders closer to keep more of my profits when things get rough and staying out of the market during corrections has enabled me to achieve super performance.

    ​

    Daily $SPY in stage 3 going into 4

    Daily $QQQ in stage 3 going into 4

    Weekly $QQQ in stage 2 going into 3

    submitted by /u/Fly-Elevated
    [link] [comments]

    I invested in #5 during the shutdown, did anyone else invest in alcohol stocks?

    Posted: 30 Apr 2021 08:38 AM PDT

    Future covid treatment pending EUA

    Posted: 30 Apr 2021 08:02 PM PDT

    EUA expected in 1-4 weeks. If it does, expected 4-8x. Shorts are trying to silence this company. Please do your own DD. I've been following this company for 6 months and I am in it for the long haul.

    this drug is immune to mutations of COVID-19, simply because it does not target COVID-19. This "in the weeds" company is called Humanigen and their therapeutic drug is called Lenzilumab.

    Lenzilumab, with other treatments including steroids and/or remdesivir, help prevent and treat an immune hyper-response, (cytokine storm). GM-CSF is responsible for activating macrophages and monocytes that contribute to disease severity, Mapping Severe COVID-19 in the Lungs at Single-Cell Resolution – NIH Director's Blog .mapping severe covid

    Fully administered in one day, Lenzilumab improves patient SpO2 levels within the first 24 hours as shown by mayo clinic study and can prevent progression to invasive mandatory ventilation by 54%. It helps get patients out of the ICU/ hospital sooner, making more room for other critical patients in need. Humanigen Inc. - Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19phase 3 results

    One item that may be a concern is the cost of the drug. However, the need for mechanical ventilation significantly increases the costs of COVID-19 care, as well as having a prolonged stay in the ICU. I'm not sure on Canada's numbers in our healthcare, but in the States, it's 5x the cost Mechanical Ventilation Adds 5X the Cost to COVID-19 Care | Premier (premierinc.com)5x cost

    The FDA has revoked EUA for Monoclonal Antibody Bamlanivimab because of its ineffectiveness against newer strains while being used for mild-to-moderate COVID-19 symptoms , FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab (govdelivery.com)bam is bad

    Of the currently available vaccines with mutations on the rise and reduced efficacy against them, I believe that Lenzilumab can help save lives and solve multiple problems that we are currently facing. Such as, reduce need for invasive mandatory ventilation, immune to mutant strains, reduce hospital stay ie. More bed availability, fast reoxygenation response, fully administered in 1 day, cost savings on healthcare, etc. I want to put eyes on this because it seems that it's getting silenced from HF shorts. So much amazing news.

    Again please do your own DD but I think this is a diamond in the rough.

    submitted by /u/Plenty-Appointment40
    [link] [comments]

    I am new to investing and have a quick question

    Posted: 30 Apr 2021 05:10 AM PDT

    I have 400 pound saved and I want to start investing I wanted to put £100 each into the UFC endeavour, Tesla, pay pal and Google My question is which is the best app to do this in your experience? I am from the UK and I'm looking for the best stock app because I don't have a laptop just an android phone I guess I'm looking for the app with the lowest fees and I'm not sure what else to look for in an app. Do all apps have the same stock market stocks I would have thought they do is there any real benefit to using a certain app other a different app or are they all the same? Cheers

    submitted by /u/Consciouslychange
    [link] [comments]

    Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis

    Posted: 30 Apr 2021 07:25 PM PDT

    Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

    Posted: 30 Apr 2021 07:12 PM PDT

    Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. The entry of all subjects' information into the clinical trial data base and source document verification processes are ongoing and this is a crucial preliminary step in finalizing the Phase II Clinical Trial.

    Today, FINRA processed a Form 211 relating to the initiation of priced quotations of HMTXF on OTCQB, where the Company has reapplied to be listed. The submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and has met the requirements under that rule to initiate quotation of HMTXF within three business days. FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the security, the issuer, or the issuer's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security.

    submitted by /u/DSPowerOfTheSun
    [link] [comments]

    Here is a Market Recap for today Friday, April 30, 2021

    Posted: 30 Apr 2021 01:02 PM PDT

    PsychoMarket Recap - Friday, April 30, 2021

    The market fell on Friday after a record-setting session, with the S&P 500 (SPY) pulling back after recording fresh intraday highs. Market participants continue to assess the slew of corporate earnings reports and recent, encouraging economic data.

    Last night, President Biden addressed a joint session of Congress, during which he said "America was back on the move again" following the coronavirus pandemic that devastated the economy. In his address, President Biden touted his $2 trillion infrastructure plan and unveiled a new $1.8 trillion proposal aimed at supporting children, students, and families. This proposal, called the American Families Plan, would be funded in part with the newly proposed tax increases on the wealthy. Read the details of the proposal here.

    Shares of Amazon (AMZN) outperformed the market, jumping to a new record high after reporting blowout Q1 earnings fueled by sustained demand, showing great strength even as the economy in the US begins to reopen. Shares of Twitter, on the other hand, sunk after the company fell short of estimates, disappointing investors who hoped the company would show a strong pick-up in ad sales like peers Snap (SNAP) and Facebook (FB).

    Market participants also digested recent commentary from members of the Federal Open Market Committee (FOMC), which included no major changes to policy but did highlight recent improvements in the US economy. FOMC members said the effective distribution of the vaccine in the US has improved economic conditions but reiterated interest rates will remain near-zero and the current pace of the asset purchasing program in place. The Fed said, "Amid progress and strong policy support, indicators of economic activity and employment have risen." The committee remains optimistic about the rebound in economic activity, describing the most affected sectors as "having shown improvement", but shows no signs of slowing quantitative easing or raising interest rates. With more than 8 million people still out of jobs compared to pre-pandemic levels, FOMC reiterated its commitment to supporting the economy.

    Highlights

    • The Labor Department released its Weekly Unemployment Report, which shows fresh pandemic-era lows as the economy gradually reopens.
      • Initial jobless claims, week ended April 24: 553,000 vs. 540,000 expected and an upwardly revised 566,000 during the prior week
      • Continuing claims, week ended April 17: 3.660 million vs. 3.590 million expected and a downwardly revised 3.651 million during the prior week
    • Shares of Uber, Lyft and Doordash (DASH) fell sharply after Reuters reported that Labor Secretary Marty Walsh supported reclassifying gig workers as employees. This change would give workers additional benefits at a large cost to companies. Recall the battle last year over Proposition 22 in California, which eventually passed in favor of companies in the gig-economy.
    • US gross domestic product (GDP) increased at a 6.4% quarter-over-quarter, seasonally adjusted annualized rate in the first three months of 2021, the Bureau of Economic Analysis said Thursday in its first estimate on GDP. This marked an acceleration from the 4.3% annualized growth rate from the fourth quarter of 2020
    • New York City Mayor Bill de Blasio said that NYC would open with full capacity beginning July 1. "Our plan is to fully reopen on July 1. We are ready for stores to open, for businesses to open, offices, theaters, full strength," de Blasio said.
    • Personal income jumped 21.1% in March over February, the Bureau of Economic Analysis said Friday. This came in better than the 20.3% rise expected, according to Bloomberg consensus data.
    • Shares of Nio outperformed the broader market, trading roughly 2% higher after the company reported better-than-expected earnings.
    • **Please note that current stock price was written premarket and does not reflect intraday changes*\*
    • Agios Pharma (AGIO) target raised by Barclays from $65 to $70. Stock currently around $56
    • Amedisys (AMED) target raised by Royal Bank of Canada from $335 to $350 at Outperform. Stock currently around $286
    • Amazon (AMZN) with a host of target raises following a blowout earnings report. Consensus price target $4200 at Buy. Stock currently around $3471
    • Brunswick (BC) with four target raises. Stock currently around $106
      • KeyCorp from $99 to $115
      • Raymond James from $109 to $122
      • Royal Bank of Canada from $99 to $116
      • Robert W Baird from $100 to $115 at Outperform
    • Burlington Stores (BURL) target raised by Morgan Stanley from $317 to $385 at Overweight. Stock currently around $321
    • Comcast (CMCSA) with two target raises. Stock currently around $56
      • Goldman Sachs (GS) from $62 to $64 at Buy
      • Raymond James from $61 to $63
    • Domino's Pizza (DPZ) with three target raises. Stock currently around $416
      • Oppenheimer from $405 to $450
      • Webdush from $475 to $480
      • Royal Bank of Canada from $446 to $466
    • Floor & Decor (FND) target raised by Wedbush from $110 to $130 at Outperform. Stock currently around $114
    • IMAX target raised by Macquarie from $25 to $30 at Outperform. Stock currently around $21
    • Mastercard (MA) with three target raises. Stock currently around $389
      • Mizuho from $430 to $435 at Buy
      • Macquarie from $385 to $425 at Outperform
      • Jefferies from $440 to $450 at Buy
    • McDonald's (MCD) with two target raises. Stock currently around $235
      • KeyCorp from $235 to $265
      • Wedbush from $255 to $260
    • OneWater Marine (ONEW) target raised by Robert W Baird from $40 to $60 at Outperform. Stock currently around $49
    • OSI Systems (OSIS) target raised by Roth Capital from $108 to $122 at Buy. Stock currently around $97
    • Silicom (SILC) target raised by Needham & Co. from $55 to $57 at Buy. Stock currently around $45
    • Atlassian (TEAM) with four target raises after reporting blowout earnings. Stock currently around $228
      • Morgan Stanley from $275 to $292
      • Canaccord Genuity from $260 to $275
      • Mizuho from $270 to $285
      • Macquarie from $263 to $270
    • Texas Roadhouse (TXRH) target raised by Wedbush from $110 to $122 at Outperform. Stock currently around $103
    • Western Digital (WDC) with three target raises. Stock currently around $71
      • Mizuho from $80 to $88 at Buy
      • Citigroup from $80 to $90 at Buy
      • Loop Capital from $65 to $90 at Buy
    • JP Morgan (JPM) target raised by Wells Fargo (WFC) from $190 to $195 at Overweight. Stock currently around $155
    • Following a disappointing earnings report, Twitter (TWTR) price target was lowered by a host of analysts. Stock currently around $65
      • Morgan Stanley from $68 to $62
      • Oppenheimer from $80 to $70
      • Rosenblatt Securities $65 to $60
      • Barclays from $52 to $48

    "The two most powerful warriors are patience and time." - Leo Tolstoy

    submitted by /u/psychotrader00
    [link] [comments]

    How should I invest $190,000 at age 19?

    Posted: 30 Apr 2021 03:09 PM PDT

    I plan on investing for the long term and going into real estate. I will make around $60,000-$70,000 annually, and pay very little towards the mortgage, thanks to tenants. For about 8 years I plan on saving around $50,000/year, $400k in 8 years+$190,000 initial amount. St 28, I could have $600,000. Should I stay very safe in VTSAX/VTWAX/VTI, or should I go into a different area? I will decline any crypto/forex. I understand these are hypothetical numbers, so no need to make that known again. If these were true numbers, what would you do with the money? Thanks

    submitted by /u/MrSidelineSwap
    [link] [comments]

    HE1/HLOGF: Helium One Global: Couple Notes

    Posted: 30 Apr 2021 12:06 PM PDT

    Helium is the 2nd most abundant gas in the universe. It's commercial uses include Cloud computing, Data Centres, Semiconductors, MRI scans, space, satellites, military rockets and quantum computing. It has the lowest boiling point of of any element and can therefore be used to keep freeze things at sub zero temperatures like vaccines.

    Helium One Globals: Project Rukwa drilling is due to start in May, this is the largest known primary helium resource in the world. It is a pure or carbon neutral helium field, promising a green, clean, carbon neutral form of gas. The site is 138 BILLION cubic feet ( or put another way enough for 20 years global supply). There is already a pent up demand due to its multiple uses, and the price of helium has recently increased from $118 mcf in 2018 to $280 mcf in 2020

    The current way helium is gained is as a by- product of oil and hydrocarbon refining and It is currently the only listed company in the UK that offers exposure to primary source helium exploration, whilst the US nears the end of a 25 year privatisation program.

    Abundant, Valuable, Multi purpose, with a pent up demand, limited supply, ESG credentials and drilling to start in May.

    submitted by /u/flaxbandit
    [link] [comments]

    WHAT MEANS THAT THE OBV IS FALLING AND THE PRICE IS RISING??

    Posted: 30 Apr 2021 02:18 PM PDT

    Leveraged ETFs CAN be a long-term strategy! Right?

    Posted: 30 Apr 2021 11:51 AM PDT

    I made 170% profit on the S&P500 this year by holding Leveraged ETF's long term. The leveraged ETF actually over-delivered in its 2x promise. I went and did a lot of research because I've always heard that Leveraged ETFs should NEVER be used as long-term investment vehicles. But I disagree – if the trend is moving in one direction (for the most part), then leveraged ETFs actually over deliver and free up other capital you would've otherwise needed to make same profit to be invested elsewhere.

    I understand the concept of decay and volatility drag, but it just doesn't seem to apply to SSO and SPXL when looking and comparing with the SPY index. What am I missing here?

    Full video on this her with proof of winnings and fully explained thoughts…
    https://youtu.be/x-1-3631Pxo

    submitted by /u/HEAL3D
    [link] [comments]

    A Letter to the Employees of Neovasc, Inc...$NVCN

    Posted: 30 Apr 2021 05:18 AM PDT

    A Letter to the Employees of Neovasc, Inc.

    I am writing to appeal to the good hard working professionals at Neovasc. Today more than ever, professionals are seeking and demanding, businesses that practice Social Responsibility. The days are gone of businesses not being held accountable for their actions…and just as impactful…their inactions. Companies are now, rightfully so, expected to conduct themselves in an Ethical, legal and economic responsible manner. Equal pay, diversity and inclusion, and stewardship of the environment are no longer perks, but the minimum standard.

    Shouldn't a business, treat its investors and shareholders with that very same level of respect and responsibility?

    For the past several years, the executive management and Board of Directors of Neovasc have destroyed the livelihoods of its investors. Due to management's greed and corruption, investors have found their investments turn to ashes. Is there no social responsibility accorded to shareholders?

    Is holding life saving products hostage in order to continue to scam investors out of their hard earn money and life savings, socially responsible?

    Furthermore, is it socially responsible, to NOT communicate the perpetual dire state of Neovasc's existence to its employees, who may or may not have a job on any given day?

    Neovasc's business model consists of making wild speculation and calling them projections and forecasts. Operations funded via toxic financing and passing on all the risk to unsuspecting investors in the stock market. This is neither an ethical, nor arguably, a legal manner to conduct a business.

    A professional should work for a company that is a badge of honor on their resume…not a stain of disgrace.

    Find out the truth at: https://neovascam.squarespace.com/

    submitted by /u/Taking-my-medication
    [link] [comments]

    Vaccine stocks analysis - $MRNA vs $BNTX

    Posted: 30 Apr 2021 03:41 AM PDT

    Vaccine stock analysis

    $BNTX Av Est. EPS: $32.07 ('21) & $18.69 ('22) Av Est. Revenue: $12.29B ('21) & $7.73B ('22) Market Cap @ SP 180: $42.3B P/E @ SP 180: 9.63 (based on '22 EPS)

    $MRNAAv Est. EPS: $23.27 ('21) & $16.58 ('22)Av Est. Revenue: $17.46B ('21) & $13.69B ('22)Market Cap @ SP 180: $72.2BP/E @ SP 180: 10.88 (based on '22 EPS)

    Looks like market is grossly underestimating revenue & EPS for $BNTX. Once these figures become clear, there has to be a major price correction. If $BNTX has higher revenue and higher earnings than $MRNA it should have a higher market cap, so price should be more than 2x that of $MRNA. If $MRNA is trading at $200, $BNTX should be trading at $400. Massive opportunity sitting right in front of us with little or no risk considering that every major country is locking in future Pfizer-BionTech vaccine supplies.

    submitted by /u/No-Peach-4319
    [link] [comments]

    Thoughts? “Last 8% is in YOLO”. I’m 23. Knowledgeable in what Im investing in. Currently getting out fully from the military, have my own dog boarding & training business. I have $16K into this pie. Plan on ofcourse tweaking it as time goes by but Im solid on these picks.

    Posted: 30 Apr 2021 03:33 PM PDT
    Read more
    at

    No comments:

    Post a Comment